Navigation Links
Roche cytomegalovirus viral load test now available in US
Date:9/17/2012

INDIANAPOLIS, Sept. 17, 2012 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the commercial availability of a new test to assess a patient's viral load of cytomegalovirus (CMV). Physicians use information from the test to help them manage patients who have been diagnosed with CMV disease, specifically patients with an immune system that has been suppressed for solid organ transplantation. The test received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) in July 2012.

"With this new test, diagnostic laboratories now have a standardized, FDA-approved option for CMV viral load testing that addresses a key medical need for transplant patients," said Whitney Green, senior vice president, molecular diagnostics, for Roche Diagnostics Corporation. "There has been significant interest in the test from labs and the transplant community since the FDA approval, as it will provide physicians with clinically useful information to help them manage patients with CMV disease."

The real-time polymerase chain reaction (PCR)-based CMV test provides standardization of CMV viral load monitoring with traceability to the WHO International CMV standard. It is designed for use on Roche's fully automated COBAS® AmpliPrep/COBAS® TaqMan® System, an established platform for viral load monitoring of multiple infectious diseases that helps laboratories improve their workflow. The system can be combined with the cobas p 630 Instrument, which provides an integrated pre-analytical primary tube handling solution.

About the test
The first FDA-approved laboratory test for use in quantifying CMV DNA in human plasma specimens, the COBAS AmpliPrep/COBAS TaqMan CMV Test is intended for use as an aid in the management of solid-organ transplant patients who are undergoing anti-CMV therapy. In this population, the test can be used to assess virological response to antiviral treatment.

About the COBAS AmpliPrep/COBAS TaqMan System
Roche's fully automated COBAS AmpliPrep/COBAS TaqMan System combines the COBAS AmpliPrep Instrument for automated sample preparation and the COBAS TaqMan Analyzer or the smaller COBAS TaqMan 48 Analyzer for automated real-time PCR amplification and detection. The system has parallel processing with other key molecular diagnostics assays targeting medically relevant diseases (Hepatitis B virus, Hepatitis C virus and Human Immunodeficiency Virus). Roche's AmpErase enzyme, which is designed to prevent cross-contamination of samples and labs, is included in each test.

About Cytomegalovirus
CMV is the most common viral infection in solid organ transplant recipients. The virus can be transmitted through the donor organ, resulting in CMV infection and leading to the development of CMV disease, or can occur by reactivation of the virus in transplant recipients with previous CMV infection. CMV disease in transplant recipients may be similar to infectious mononucleosis with fever, malaise and mild laboratory abnormalities, or can be more serious with involvement of the lung or gastrointestinal tract. Fifty to eighty percent of all people in the U.S. become infected with CMV. Although healthy persons usually have few symptoms at the time of initial infection, after infection the virus remains in a latent state in the body for the rest of a person's life. The virus can then be transmitted and cause infection through organ donation, or latent virus in the transplant recipient can become reactivated and cause symptomatic disease.  

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.

For further information, please contact:

Todd Siesky

Director, Corporate Communications

Roche Diagnostics Corporation

Indianapolis, IN

(317) 521-3966

todd.siesky@roche.com

 


'/>"/>
SOURCE Roche Diagnostics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. Rochester Medical Introduces Magic3® Coude Tip Hydrophilic Intermittent Catheter
3. Roche announces FDA approval of HIV viral load test
4. FDA clears Accu-Chek Combo system - Roches new interactive insulin pump system for people with diabetes
5. Rochester Medical Announces Third Quarter 2012 Earnings Conference Call Friday, July 27, 2012
6. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
7. Rochester Medical Reports Third Quarter Results
8. Roche receives FDA clearance for herpes simplex virus type 1 and 2 tests
9. Roche Selects Thomson Reuters to Transform the Management of Its Intellectual Property Assets
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... has successfully concluded its meeting with the U.S. Food ... oral insulin formulation. ... the regulatory pathway for submission of ORMD-0801, would be ...
(Date:9/1/2017)... 1, 2017  Explorers Like Us ( https://explorerslikeus.com/ ) is ... experiences — and deliver these experiences as part of Life ... feel and heal better. ... While nothing beats a walk, jog or simply ... Life Environments™ is the next best thing when getting there ...
(Date:8/31/2017)... NEW YORK , Aug. 31, 2017 ... the industry,s must-read guide to the latest innovations happening ... the first industry publication to focus on providing a ... advancements. Ultimately, the issue covers the most innovative companies, ... year. "Everyone in ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... September 21, 2017 , ... Hair ... new member survey conducted by the International Society of Hair Restoration Surgery ... to 2016 rose 60 percent, with 635,189 procedures performed in 2016. , ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... eat right or exercise more try taking a more holistic approach and use ... Aweganic’s new Amazon essential oil collection is certified USDA guaranteeing that, the new ...
(Date:9/21/2017)... ... 2017 , ... Preora Diagnostics Inc. , a privately ... received two prestigious recognitions that acknowledge the promise of its PWS Nanoctyology platform ... been named a Top 100 Finalist for the 16th annual Chicago Innovation Awards ...
(Date:9/21/2017)... ... September 21, 2017 , ... FlipBelt, the fitness brand ... to detail to the athletic wear market with the launch of their FlipBelt Crops. ... have their essentials securely at their fingertips while at the gym, on the trail, ...
(Date:9/21/2017)... ... September 21, 2017 , ... In ... and Clark College Emeritus Professor of Education Gregory A. Smith examines student privacy ... Asleep at the Switch: Schoolhouse Commercialism, Privacy, and the Failure of Policymaking . ...
Breaking Medicine News(10 mins):